The inhibitory role of Spm analogues and the low level of SMO in BC tissues taken together, could explain the poor positive outcome of both BENSpm, in Phases I and II of clinical trials, and CPENSpm, due to a lower H2O2 production inside tumor mass [11]. Here, SMO is linked to breast cancer.